TD Cowen analyst Steve Scala reiterated a Buy rating and $1,250.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "Lilly Confident Oral GLP-1s Will Expand Mkt; Q4 revenue/EPS beat, '26 guidance above our/consensus estimates. Despite "low to mid teens" WW pricing headwind, Lilly anticipates '26 GPM will be "stable to slightly down" and OpInc margin will grow -0.3pp to +1.2pp. U.S. incretin market to continue on "similar trajectory" as '25. Lilly has high expectations for orforglipron U.S. launch (in Q2) and is confident oral GLP1s will expand market."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $1107.12 yesterday.